10 results
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our product
424B5
SCNI
Scinai Immunotherapeutics Ltd
28 Dec 21
Prospectus supplement for primary offering
5:20pm
and affordability for our product candidates, if approved, and, accordingly, the results of our financial operations. We cannot predict whether future healthcare
424B5
SCNI
Scinai Immunotherapeutics Ltd
27 Dec 21
Prospectus supplement for primary offering
6:22am
healthcare funding, which may materially adversely affect customer demand and affordability for our product candidates, if approved, and, accordingly
424B5
76nfnf97
1 Feb 21
Prospectus supplement for primary offering
5:08pm
424B5
b2mv3bwf9a whzrdqx
29 Jan 21
Prospectus supplement for primary offering
12:00am
6-K
EX-99.3
immm7px1w
2 Oct 20
Condensed Interim Financial Statements
12:00am
424B5
zapgjk4
2 Oct 20
Prospectus supplement for primary offering
12:00am
F-1
kgxr0q9mlet2ms
29 Dec 14
Registration statement (foreign)
12:00am
- Prev
- 1
- Next